Tech

Search documents
SRPT Investors Have the Opportunity to Lead the Sarepta Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Prnewswire· 2025-07-08 13:50
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 8, 2025 /PRNewswire/ -- ...
Baker Hughes and Evida Partner to Advance CO2 Transport in Denmark
ZACKS· 2025-07-08 13:31
Key Takeaways BKR and Evida are partnering to build scalable CO2 transport solutions across Denmark. The deal merges BKR's CO2 equipment expertise with Evida's pipeline transport capabilities. Evida CO2 is preparing initial pipeline links aligned with Denmark's CCS tender timeline.Baker Hughes Company (BKR) ), a leading energy technology company, has joined forces with Denmark’s state-owned gas distributor Evida to develop and scale CO2 transport solutions across Denmark, per an Offshore Energyreport. The ...
Allot Communications (ALLT) Surges 8.0%: Is This an Indication of Further Gains?
ZACKS· 2025-07-08 13:16
Allot Communications (ALLT) shares ended the last trading session 8% higher at $9.21. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.6% loss over the past four weeks.The sharp rise in the stock price was fueled by optimistic investor sentiment, sparked by recent analyst upgrades, promising earnings potential, an expanding customer base, and the effective rollout of the company’s security solutions.This internet ...
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
Globenewswire· 2025-07-08 13:15
Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric cardiomyopathies affect at least 100,000 children worldwideEffective treatment options are limited, with nearly 40% of children with DCM requiring a heart transplant or dying within two years of diagnosis MIAMI, July 08, 2025 (GLOB ...
Why Is Penny Stock ProKidney Trading Higher On Tuesday?
Benzinga· 2025-07-08 13:05
ProKidney Corp. PROK stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro.What happened: The chronic kidney disease (CKD)-focused company reported statistically significant and clinically meaningful positive topline results from the full Group 1 modified intent-to-treat (mITT) population of the Phase 2 REGEN-007 trial of rilparencel in patients with CKD and diabetes.Rilparencel is an autologous cellular therapy ...
人行广东省分行等部门联合发文:全链条支持广州科技创新发展
2 1 Shi Ji Jing Ji Bao Dao· 2025-07-08 13:05
南方财经记者 庞成 广州报道 二是强化科技金融政策合力。从多维度发力,在完善信贷风险补偿分担机制、加强信息共享和投融资对 接、开展"益企共赢计划"试点、打造科创高地等方面凝聚各方合力,支持广州科技创新发展。 三是优化科技金融发展生态。完善科技金融组织体系和内部管理机制,建立健全科技金融统计制度和评 估机制,探索组建广州科技金融联盟,发挥市级财政科技资金带动作用,构建"赛事奖补+创业投资+科 技信贷"联动机制,打造"科学家+企业家+银行家+投资家"人才集聚新模式,营造广州科技金融高质量 发展的良好生态。 四是加强组织保障。加强统筹协调和信息共享,健全工作简报制度,及时会商重要问题,推动各项措施 落实落细,做好经验总结和宣传推广,打造可复制可推广的典型模式,加强信贷风险管理,切实防范科 技金融创新风险。 人行广东省分行表示,将以《实施意见》的出台为契机,认真贯彻中央金融工作会议决策部署,落实好 广东省委"1310"具体部署和广州市委"1312"思路举措,与有关部门加强信息共享和政策协同,引导金融 资本投早、投小、投长期、投硬科技,推动《实施意见》各项措施落到实处,全力做好广州科技金融大 文章,以高质量科技金融服务 ...
Cloudastructure's AI and Remote Guarding Platform Achieves a More Than 98% Crime Prevention Rate Amid Rising Property Threats
Globenewswire· 2025-07-08 13:00
PALO ALTO, CA, July 08, 2025 (GLOBE NEWSWIRE) -- Cloudastructure, Inc. (Nasdaq: CSAI) (“we,” “us,” “our,” “Cloudastructure” or the “Company”) an award-winning leader in AI Surveillance and Remote Guarding, announced today the company’s AI-driven security platform achieved an exceptional deterrence rate of over 98% of all threatening activity between January and May 2025—effectively preventing incidents of theft, trespassing, and confrontations before they could escalate into criminal acts. This performance ...
NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform
Globenewswire· 2025-07-08 13:00
CALABASAS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has signed a non-binding term sheet with Quazar Investment to form a new UAE-based investment and clinical platform focused on the Middle East and North Africa (MENA) region. The non-binding term sheet outlines the formation of NuroMENA Holdings Ltd, a wholly owned hol ...
Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing
Globenewswire· 2025-07-08 13:00
PITTSBURGH, July 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has entered into a standby equity purchase agreement (“SEPA”) with YA II PN, LTD, an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”). Predictive Oncology expects the partnership to provide an efficient and flexible source of funding, enabling the company to progress its ongoing drug discovery, biomarker discovery and drug repurposing init ...
Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Prnewswire· 2025-07-08 13:00
NEW YORK, July 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/sarepta-lawsuit-submission-f ...